JP2024546095A5 - - Google Patents
Info
- Publication number
- JP2024546095A5 JP2024546095A5 JP2024533954A JP2024533954A JP2024546095A5 JP 2024546095 A5 JP2024546095 A5 JP 2024546095A5 JP 2024533954 A JP2024533954 A JP 2024533954A JP 2024533954 A JP2024533954 A JP 2024533954A JP 2024546095 A5 JP2024546095 A5 JP 2024546095A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- independently
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163287962P | 2021-12-09 | 2021-12-09 | |
| US63/287,962 | 2021-12-09 | ||
| PCT/US2022/052228 WO2023107606A1 (en) | 2021-12-09 | 2022-12-08 | Bcl-xl/bcl-2 dual degraders for treatment of cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546095A JP2024546095A (ja) | 2024-12-17 |
| JP2024546095A5 true JP2024546095A5 (https=) | 2025-12-04 |
Family
ID=85036966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024533954A Pending JP2024546095A (ja) | 2021-12-09 | 2022-12-08 | 癌の処置のためのｂｃｌ－ｘｌ／ｂｃｌ－２二重分解物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250154141A1 (https=) |
| EP (1) | EP4444717A1 (https=) |
| JP (1) | JP2024546095A (https=) |
| KR (1) | KR20240118146A (https=) |
| CN (1) | CN118660886A (https=) |
| AU (1) | AU2022405016A1 (https=) |
| CA (1) | CA3241668A1 (https=) |
| WO (1) | WO2023107606A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113660937A (zh) * | 2019-02-08 | 2021-11-16 | 佛罗里达大学研究基金公司 | 治疗剂和治疗方法 |
| US12441722B2 (en) | 2020-01-15 | 2025-10-14 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| WO2025129024A1 (en) * | 2023-12-13 | 2025-06-19 | University Of Florida Research Foundation, Incorporated | Cereblon-recruiting degraders of antiapoptotic bcl-2 proteins |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002097053A2 (en) | 2001-05-30 | 2002-12-05 | The Regents Of The University Of Michigan | Small molecule antagonists of bcl2 family proteins |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| AU2005277223C1 (en) | 2004-08-20 | 2009-05-21 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof |
| US8039668B2 (en) | 2008-10-17 | 2011-10-18 | Burnham Institute For Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| WO2010138588A2 (en) | 2009-05-26 | 2010-12-02 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| AU2012255251B2 (en) | 2011-05-18 | 2017-06-15 | University Of Florida Research Foundation, Inc. | Macrocyclic therapeutic agents and methods of treatment |
| CN113660937A (zh) | 2019-02-08 | 2021-11-16 | 佛罗里达大学研究基金公司 | 治疗剂和治疗方法 |
| US12219938B2 (en) * | 2020-10-19 | 2025-02-11 | University Of Florida Research Foundation, Incorporated | Mouse model of alcohol-induced liver cancer |
-
2022
- 2022-12-08 CA CA3241668A patent/CA3241668A1/en active Pending
- 2022-12-08 CN CN202280091197.7A patent/CN118660886A/zh active Pending
- 2022-12-08 AU AU2022405016A patent/AU2022405016A1/en active Pending
- 2022-12-08 US US18/717,509 patent/US20250154141A1/en active Pending
- 2022-12-08 EP EP22847326.0A patent/EP4444717A1/en active Pending
- 2022-12-08 JP JP2024533954A patent/JP2024546095A/ja active Pending
- 2022-12-08 WO PCT/US2022/052228 patent/WO2023107606A1/en not_active Ceased
- 2022-12-08 KR KR1020247022837A patent/KR20240118146A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022520061A5 (https=) | ||
| JP2024546095A5 (https=) | ||
| JP2006523216A5 (https=) | ||
| RU2468021C2 (ru) | Гетероциклические соединения и их применение | |
| JP2004536879A5 (https=) | ||
| JP2019510832A5 (https=) | ||
| JP2006503919A5 (https=) | ||
| ES2830447T3 (es) | Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación | |
| JP2009536191A5 (https=) | ||
| JP2008521928A5 (https=) | ||
| CN105338977A (zh) | 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 | |
| JP2007520452A5 (https=) | ||
| JP2015517523A5 (https=) | ||
| JP2021530554A5 (https=) | ||
| CN101939001B (zh) | 用于治疗卵巢癌的含有紫杉醇的组合 | |
| JP6422936B2 (ja) | ５−ブロモ−インジルビン | |
| CN101687104A (zh) | 包括长春氟宁和曲妥单抗的癌症治疗联合疗法 | |
| CA2483826A1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| KR100812693B1 (ko) | 항종양 효과 증강제 및 항종양제 | |
| JP2021511344A5 (https=) | ||
| JP6370801B2 (ja) | 肝疾患または肝障害の治療のための使用および方法 | |
| JP2023550740A5 (https=) | ||
| EP1757283B1 (en) | Antitumor effect fortifier, antitumor agent and method of therapy for cancer | |
| JP5843086B2 (ja) | 治療活性物質の作用を増強するための高分子化環状ニトロキシドラジカル化合物の使用 | |
| JP5409613B2 (ja) | 抗腫瘍剤、キット及び癌治療方法 |